Fig. 3
Expression of exo-PWAR6 and its clinical significance in patients with CRC. A, B Representative image and PWAR6 expression of patients with varied 68Ga-FAPI-PET SUV max values (n = 15 patients). C Representative image of PDOs and PWAR6 ISH using tissues from patients with varied 68Ga-FAPI-PET SUV max values. Scale bars = 50μm. (n = 15 patients). D, E Representative ISH image and PWAR6 expression in healthy donors (enteritis) and CRC patients with and without LM. Scale bars = 50μm (n = 25 patients). F Representative CT or MRI Images of CRC Patients with and without LM (n = 25 patients). G Heatmap of Chi-Square test based on the association between PWAR6 and different clinicopathological factors. (n = 150 patients). H Univariate and multivariate Cox regression analyses of OS in the FUSCC cohort 3. (n = 150 patients). I PWAR6 expression level of patients with high myCAF score and low myCAF score, data obtained from the GSE39582. (n = 133 patients). K Kaplan‒Meier survival curve of patients with PWAR6-high and PWAR6-low, data obtained from the FUSCC cohort3. (n = 150 patients). Data are shown as mean ± s.e.m. For A-D and I, data were analyzed by one-way ANOVA. For G, data were analyzed by Chi-square test. For H, data were analyzed by Cox regression analysis. For J, data were analyzed by log-rank test. P values. *P < 0.05, **P < 0.01, ***P < 0.001